Astrocytoma – European Clinical Trials Information Network https://clinicaltrials.eu Bridging Patients with Clinical Trials Tue, 02 Jun 2026 04:15:58 +0000 en-US hourly 1 https://wordpress.org/?v=7.0 https://clinicaltrials.eu/wp-content/uploads/2024/12/cropped-EU_icon-32x32.png Astrocytoma – European Clinical Trials Information Network https://clinicaltrials.eu 32 32 Testing Tuvusertib in Patients with Returning IDH and ATRX Mutant Astrocytoma Brain Tumor https://clinicaltrials.eu/trial/testing-tuvusertib-in-patients-with-returning-idh-and-atrx-mutant-astrocytoma-brain-tumor/ Wed, 29 Apr 2026 15:07:50 +0000 https://clinicaltrials.eu/trial/testing-tuvusertib-in-patients-with-returning-idh-and-atrx-mutant-astrocytoma-brain-tumor/ This study involves patients with a specific type of brain tumor called astrocytoma that has certain genetic changes, including IDH mutation, ATRX mutation, and p53 mutation. Astrocytoma is a type of brain tumor that develops from star-shaped cells in the brain. The study will use a medicine called tuvusertib, which is given as a tablet by mouth. The purpose of the study is to evaluate how well tuvusertib works in patients whose astrocytoma has come back after previous treatment with radiation therapy and chemotherapy.

Patients in this study will take tuvusertib tablets daily for up to 480 days. During the study, patients will have regular visits where doctors will check how the tumor is responding to treatment using magnetic resonance imaging, which is a type of scan that creates detailed pictures of the brain. The doctors will follow specific guidelines called RANO criteria to determine if the tumor is growing, shrinking, or staying the same. Patients will also have blood tests to check their overall health and will be asked questions about their thinking abilities, daily activities, and any symptoms they may be experiencing.

The study will measure how long patients live without their tumor getting worse, which is the main goal of the research. Other measurements include how many patients see their tumor shrink, overall survival time, how long before another treatment is needed, and any side effects from the medicine. Patients will also complete questionnaires about their quality of life and how they are functioning in their daily activities. Regular brain scans and medical examinations will be performed throughout the study to monitor the tumor and the patient’s condition.

]]> Study on the Safety and Effectiveness of Nivolumab, Ipilimumab, and Myeloid Dendritic Cells for Patients with Recurrent Glioblastoma After Surgery https://clinicaltrials.eu/trial/study-on-the-safety-and-effectiveness-of-nivolumab-ipilimumab-and-myeloid-dendritic-cells-for-patients-with-recurrent-glioblastoma-after-surgery/ Wed, 29 Apr 2026 14:57:32 +0000 https://clinicaltrials.eu/trial/study-on-the-safety-and-effectiveness-of-nivolumab-ipilimumab-and-myeloid-dendritic-cells-for-patients-with-recurrent-glioblastoma-after-surgery/ This clinical trial is focused on studying a type of brain cancer called glioblastoma. The study involves the use of two medications, ipilimumab and nivolumab, which are given to patients after the surgical removal of the tumor. Ipilimumab is administered directly into the tumor area, while nivolumab is given through an intravenous infusion, which means it is delivered into a vein. Additionally, the study will explore the use of a special cell therapy involving CD1c+/CD141+ myeloid dendritic cells, which are a type of immune cell taken from the patient’s own blood.

The purpose of the study is to assess the safety and anti-tumor activity of these treatments when used together. After the tumor is surgically removed, patients will receive an injection of ipilimumab directly into the tumor site, along with nivolumab. Following this, nivolumab will be administered both into the cavity left by the tumor and through the vein. The study will monitor how the body responds to these treatments and any side effects that may occur.

Participants in the study will undergo regular check-ups and tests to track their progress. The study aims to gather information on how well these treatments work together in fighting glioblastoma and to ensure they are safe for patients. The trial will continue until the end of 2026, with the goal of improving treatment options for those affected by this aggressive form of brain cancer.

]]>